A Chinese Phase IIb trial of the mAb has already started, with Mabwell also hoping to initiate a Phase IIa trial in the US.

A European consortium of researchers has developed a new decision making framework for health professionals which they hope ...

Please provide your email address to receive an email when new articles are posted on . Patients with COPD experienced several improvements with 3 mg of twice-daily ensifentrine over 24 weeks.

The 2026 version of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report has been published. Key ...

In conjunction with World Chronic Obstructive Pulmonary Disease (COPD) Day, organised by the World Health Organisation and ...

If you have COPD, there are some things that can cause the disease to flare up. This is referred to as “COPD exacerbation.” Some of the most common causes of COPD exacerbation include: When you have ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the ...

About The Study: Among people with chronic obstructive pulmonary disease (COPD) at high risk of exacerbation, treatment with the β1-selective β-blocker bisoprolol did not reduce the number of ...

The GOLD COPD Update 2026 provides updated guidance on case-finding, disease activity, exacerbation management.

American Lung Association Launches 'Learning to Live with COPD' Campaign CHICAGO, Nov. 4, 2024 /PRNewswire/ -- Today, the American Lung Association has launched the "Learning to Live with COPD" ...